Published in J Neurol Neurosurg Psychiatry on February 01, 2002
Young onset dementia. Postgrad Med J (2004) 1.20
Antioxidant therapy in Alzheimer's disease: theory and practice. Mini Rev Med Chem (2008) 1.00
Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. Cell Mol Life Sci (2009) 0.96
Interaction of tau protein with model lipid membranes induces tau structural compaction and membrane disruption. Biochemistry (2012) 0.87
Isolation and biochemical characterization of amyloid plaques and paired helical filaments. Curr Protoc Cell Biol (2009) 0.87
Age-dependent changes in neuronal distribution of CacyBP/SIP: comparison to tubulin and the tau protein. J Neural Transm (Vienna) (2008) 0.83
The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies. J Neuropathol Exp Neurol (2011) 0.80
Platelet biomarkers in Alzheimer's disease. World J Psychiatry (2012) 0.78
Amyloidosis associated with cerebral amyloid angiopathy: cell signaling pathways elicited in cerebral endothelial cells. J Alzheimers Dis (2014) 0.77
Non-coding RNA as a trigger of neuropathologic disorder phenotypes in transgenic Drosophila. J Neural Transm (Vienna) (2008) 0.76
Recent Progress in Alzheimer's Disease Research, Part 2: Genetics and Epidemiology. J Alzheimers Dis (2017) 0.75
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature (1997) 15.73
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell (1996) 12.59
Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 11.53
Impairment of the ubiquitin-proteasome system by protein aggregation. Science (2001) 11.51
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell (1997) 9.57
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature (1999) 8.28
A Drosophila model of Parkinson's disease. Nature (2000) 7.82
Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell (1997) 7.59
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 7.43
Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet (1998) 7.26
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron (2000) 6.92
Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging (1995) 6.86
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A (1986) 6.56
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron (1994) 6.41
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science (2000) 6.28
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (1999) 5.77
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 5.68
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med (1998) 5.49
Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature (1999) 5.48
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 5.42
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev (2000) 5.40
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86
Skeletal and CNS defects in Presenilin-1-deficient mice. Cell (1997) 4.50
Notch1 is required for the coordinate segmentation of somites. Development (1995) 4.33
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci (1999) 4.27
Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet (1999) 4.17
Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature (2000) 4.12
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet (1997) 4.11
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
The cellular prion protein binds copper in vivo. Nature (1998) 3.92
Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci (1999) 3.77
Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron (1999) 3.70
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron (1999) 3.50
Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci (1999) 3.48
The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol (1998) 3.45
Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A (2000) 3.43
Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science (2000) 3.16
Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature (1997) 3.14
Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A (2000) 3.13
Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci (1998) 3.03
Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A (2000) 2.96
alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem (1999) 2.91
Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem (1999) 2.86
Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol (2000) 2.84
Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem (1998) 2.71
Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med (1996) 2.71
Susceptibility locus for Alzheimer's disease on chromosome 10. Science (2000) 2.49
Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet (1998) 2.42
Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet (1998) 2.39
Tau protein pathology in neurodegenerative diseases. Trends Neurosci (1998) 2.37
Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science (2000) 2.35
A full genome scan for late onset Alzheimer's disease. Hum Mol Genet (1999) 2.26
Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett (1998) 2.26
Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci (2000) 2.22
Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature (1996) 2.20
APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease. Nat Genet (1998) 2.05
NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett (1997) 2.01
5' splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J Biol Chem (1999) 2.00
Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem (2000) 2.00
Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum Mol Genet (2000) 1.99
The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci (1989) 1.95
Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1. Nat Cell Biol (2000) 1.92
Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron (1998) 1.90
Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci U S A (2000) 1.88
Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Natl Acad Sci U S A (2000) 1.88
Degradation of alpha-synuclein by proteasome. J Biol Chem (1999) 1.87
A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet (1998) 1.87
The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol (1998) 1.87
Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet (1999) 1.86
Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol (1994) 1.84
Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem (2000) 1.79
Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A (1994) 1.74
BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci U S A (2000) 1.64
Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett (1999) 1.57
Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol (1999) 1.53
Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet (1995) 1.51
Cellular biology of prion diseases. Clin Microbiol Rev (1999) 1.48
The X11alpha protein slows cellular amyloid precursor protein processing and reduces Abeta40 and Abeta42 secretion. J Biol Chem (1998) 1.45
Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein. J Biol Chem (1999) 1.38
Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett (1999) 1.36
Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem (2000) 1.36
Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett (1998) 1.35
Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res (1997) 1.33
Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience (1996) 1.33
The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience (1997) 1.21
Presenilins: molecular switches between proteolysis and signal transduction. Trends Neurosci (1999) 1.21
X11 interaction with beta-amyloid precursor protein modulates its cellular stabilization and reduces amyloid beta-protein secretion. J Biol Chem (1998) 1.21
Rescue of neurophysiological phenotype seen in PrP null mice by transgene encoding human prion protein. Nat Genet (1995) 1.20
Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: applying to quantification of protein components of the aggregates. Biochem Biophys Res Commun (2000) 1.20
Interaction of a neuron-specific protein containing PDZ domains with Alzheimer's amyloid precursor protein. J Biol Chem (1999) 1.20
Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry (1996) 1.60
A randomized controlled trial with 4-month follow-up of adjunctive repetitive transcranial magnetic stimulation of the left prefrontal cortex for depression. Psychol Med (2007) 1.49
Recent advances: Psychiatry. BMJ (2001) 1.38
Phosphorylation of thr(668) in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by stress-activated protein kinase 1b (Jun N-terminal kinase-3). J Neurochem (2001) 1.09
X11 alpha and x11 beta interact with presenilin-1 via their PDZ domains. Mol Cell Neurosci (2000) 1.09
Amyotrophic lateral sclerosis mutant vesicle-associated membrane protein-associated protein-B transgenic mice develop TAR-DNA-binding protein-43 pathology. Neuroscience (2010) 1.06
Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl Psychiatry (2012) 0.99
Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo. Oncogene (2011) 0.97
Fe65 and X11beta co-localize with and compete for binding to the amyloid precursor protein. Neuroreport (2000) 0.96
p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction. Eur J Neurosci (2001) 0.95
Expression of the Fe65 adapter protein in adult and developing mouse brain. Neuroscience (2002) 0.91
Cyclin D2 interacts with cdk-5 and modulates cellular cdk-5/p35 activity. J Neurochem (1998) 0.87
An evoked auditory response fMRI study of the effects of rTMS on putative AVH pathways in healthy volunteers. Neuropsychologia (2010) 0.85
When less is more--microRNAs and psychiatric disorders. Acta Psychiatr Scand (2013) 0.83
Regional variation in electroconvulsive therapy use. Ir Med J (2011) 0.77
Serum lysozyme: is it a useful marker of malignant lymphoma in coeliac disease? Ir J Med Sci (1983) 0.75
Carnitine levels in patients with skeletal myopathy due to anorexia nervosa before and after refeeding. Int J Eat Disord (1999) 0.75
Bitemporal v. high-dose right unilateral electroconvulsive therapy for depression: a systematic review and meta-analysis of randomized controlled trials - CORRIGENDUM. Psychol Med (2017) 0.75
Capillary electrophoretic study of the complex formation between DNA and cationic surfactants. J Chromatogr A (1998) 0.75